Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 15/20 | 0.39 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | TOP2A | P11388 | 1/20 | 0.36 |
| ▸ | TOP2B | Q02880 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5418816 | 0.88 | SMN1; SMN2 (0.41) | SMN1; SMN2THRBTOP2ATOP2BKDM4E | |
| SCHEMBL30902672 | 0.85 | CXCR4 (0.50) | SMN1; SMN2THRBHRH3KDM4EALDH1A1 | |
| SCHEMBL30902677 | 0.85 | CXCR4 (0.50) | SMN1; SMN2THRBHRH3KDM4EALDH1A1 | |
| SCHEMBL9029619 | 0.83 | THRB (0.49) | SMN1; SMN2THRBTOP2ATOP2BALDH1A1 | |
| SCHEMBL4490799 | 0.83 | SMN1; SMN2 (0.41) | SMN1; SMN2THRBHRH3 | |
| SCHEMBL1959159 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2THRBHRH3 | |
| SCHEMBL17379026 | 0.82 | SMN1; SMN2 (0.40) | SMN1; SMN2THRBTOP2ATOP2BKDM4E | |
| Hydrochloric Acid SCHEMBL9029064 | 0.81 | THRB (0.48) | THRBALDH1A1 | |
| SCHEMBL974631 | 0.81 | THRB (0.51) | THRB | |
| SCHEMBL18634073 | 0.80 | THRB (0.53) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB | 2007-09-13 | — | — | US | claimed |
| US-20070191346-A1 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB | 2007-08-16 | — | — | US | claimed |
| US-7173136-B2 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | claimed |
| US-7173135-B2 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | claimed |
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | claimed |
| US-20050282856-A1 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB (SE) | 2005-12-22 | — | — | US | claimed |
| EP-1575943-A1 | 3-CYANO-QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | claimed |
| WO-2004041811-A1 | 3-CYANO-QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | claimed |
| US-7504408-B2 | Quinzoline derivatives for use in the treatment of cancer | ASTRAZENECA AB (SE) | 2009-03-17 | — | — | US | disclosed |
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB | 2007-09-13 | — | — | US | disclosed |
| US-20070191346-A1 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB | 2007-08-16 | — | — | US | disclosed |
| US-7173136-B2 | 3-Cyano-quinoline derivatives | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-7173135-B2 | Substituted 3-cyanoquinolines as MEK inhibitors | ASTRAZENECA AB (SE) | 2007-02-06 | — | — | US | disclosed |
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | ASTRAZENECA AB (SE) | 2006-04-27 | — | — | US | disclosed |
| EP-1575943-A1 | 3-CYANO-QUINOLINE DERIVATIVES | AstraZeneca AB (SE) | 2005-09-21 | — | — | EP | disclosed |
| EP-1528925-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | Astrazeneca AB (SE) | 2005-05-11 | — | — | EP | disclosed |
| EP-1521751-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS | Astrazeneca AB (SE) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004041811-A1 | 3-CYANO-QUINOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
| WO-2004004732-A1 | QUINAZOLINE DERIVATIVES FOR USE IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
| WO-2004005284-A1 | SUBSTITUTED 3-CYANOQUINOLINES AS MEK INHIBITORS | ASTRAZENECA AB (SE) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213367-A1 | Substituted 3-cyanoquinolines as MEK inhibitors | NRAS, BRAF, MAPK1 | SMN1; SMN2 3506/4885THRB 3235/4885HRH3 980/4885 |
| US-20050282856-A1 | 3-Cyano-quinoline derivatives | MKI67, CCNA1, CCNT1 | SMN1; SMN2 1797/4885THRB 4064/4885HRH3 961/4885 |
| US-20060089382-A1 | 7-[3-(4-acetylpiperazin-1-yl)propoxy]-3-cyano-6-methoxy-4-[4-(3-methoxyprop-1-ynyl)-2,3-methylenedioxyanilino]quinoline; potent anti-tumour activity; inhibition of MEK enzymes involved in the MAPK kinase pathway, inhibiting the non-receptor tyrosine-specific protein kinases | MAPK1, MAPK3, MAPK4 | SMN1; SMN2 4610/4885THRB 781/4885HRH3 1491/4885 |
| US-20070191346-A1 | 3-Cyano-quinoline derivatives | MKI67, CCNA1, CCNT1 | SMN1; SMN2 1797/4885THRB 4064/4885HRH3 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.